markets.businessinsider.com
Cure8 news brief
Why This Matters
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.
Who Should Pay Attention
Adult patients with moderately to severely active Crohn's disease, patients on or considering biologic therapies, gastroenterologists, and IBD researchers.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Omvoh is now approved in the U.S. for moderately to severely active Crohn's disease in adults and previously received approval for ulcerative colitis. The article cites Phase 3 VIVID-1 data as the basis for approval and mentions an ongoing longer-term study (VIVID-2).
If you are taking or considering biologic treatments, this expands the number of approved options for adult IBD patients; talk with your gastroenterology team about whether Omvoh may be relevant to your care and how it compares with treatments you are already using.
The piece is a market/regulatory brief aimed at investors and does not provide clinical details such as dosing, safety profile, or comparative effectiveness. For treatment decisions or detailed safety information, consult prescribing information and your clinician.
Keep In Mind
This is a regulatory/market report summarizing FDA approval based on Phase 3 trial results; it does not include clinical details, safety data, or guidance on how Omvoh compares with other therapies. Patients should consult clinicians and official prescribing information for clinical implications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmarkets.businessinsider.com
Indexed viaBing News
Source typeBusiness news
PublishedJan 15, 2025, 1:16 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment - Nasdaq
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...
FDA Approves TREMFYA For Adult Patients With Moderately To Severely Active Crohn's Disease
An FDA approval means TREMFYA is now an additional, officially authorized treatment option for adults with moderately to severely active Crohn's disease. The drug offers both IV and SC induction choices and established...
USFDA approves Eli Lilly Omvoh for Crohn's disease
This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial...